title: Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
abstract: HIV-1 has evolved many ways to evade protective host immune responses, thus creating a number of problems for HIV vaccine developers. In particular, durable, broadly specific neutralizing antibodies to HIV-1 have proved difficult to induce with current HIV-1 vaccine candidates. The recent observation that some broadly neutralizing anti-HIV-1 envelope monoclonal antibodies have polyspecific reactivities to host antigens have raised the hypothesis that one reason antibodies against some of the conserved HIV-1 envelope trimer neutralizing epitopes are not routinely made may be down-regulation of some specificities of anti-HIV-1 antibody producing B cells by host B cell tolerance mechanisms.
authors.affiliation: Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC 27710, USA. hayne002@mc.duke.edu
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: M Anthony
authors.initials: MA
authors.lastname: Moody
authors.forename: Laurent
authors.initials: L
authors.lastname: Verkoczy
authors.forename: Garnett
authors.initials: G
authors.lastname: Kelsoe
authors.forename: S Munir
authors.initials: SM
authors.lastname: Alam
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests / Q000379:methods
chemical_list: D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015488:HIV Antigens